Half-year results 2025

• Operating expenses down 20%
• Cash position of €1.7 million at June 30, 2025
• Focus on operational execution and development of clinical/pharmaceutical activities
• supported by CLIA/CAP certification

EVRY, FRANCE, THURSDAY OCTOBER 29, 2025, 5:45 PM - IntegraGen (FR0010908723 - ALINT - PEA PME eligible),
a company specializing in the genomics of cancer and rare genetic diseases, which carries out analyses of
and interpretable data for academic and private laboratories, today announces
its unaudited results for the first half of 2025, the accounts having been approved by the Board
of October 16, 2025.

FINANCIAL INFORMATION

Simplified income statement
In thousands of euros

	June 30-2025	June 30-2025
Revenue	2 564	4 570
Of which SeqOIA revenues	0	727
Operating subsidies and other income	185	269
Total Products	2 749	4 839
Operating expenses	4 181	5 196
Gross operating surplus	-1 432	-357
Depreciation and amortization provisions	35	53
Operating income	-1 467	-410
Financial result	21	40
Net exceptional income	0	219
Tax credits	39	36
Net income	-1 407	-115

Revenues for the first half of 2025 amounted to €2,749,000.down 43% in relation to the first
half-year 2024. In the first quarter of 2024, there were 727 k€ of non-recurring income related to the
leftover from the SeqOIA contract. Adjusted for this impact, the decline in sales was 33%.

Operating expenses came to €4,181k, down 201TP3Q on the first half.
2024, reflecting a reduction in raw materials consumption, a reduction in the weight
9%, and a reduction in external expenses of 22 % linked to the implementation of a
savings.

Earnings before interest, tax, depreciation and amortization (EBITDA) came to €1,432,000.
compared with -357 K€ in the first half of 2024. After taking into account financial results, the result
net loss was -1,407 K€ compared with -115 K€ in the first half of 2024.

Bérengère Génin, Managing Director, IntegraGendeclares: "The first half of 2025 has been
marked by the continued adaptation of IntegraGen following the discontinuation of services for the GCS
SeqOIA and a difficult environment for academic and hospital research.
We have implemented operational efficiency and cost-cutting measures, while at the same time
adapting our operations to the needs of our industrial customers. Thanks to our
CLIA/CAP, IntegraGen is now in a position to support the clinical development of its products.
pharmaceutical partners.

Simplified liabilities
In thousands of euros

	June 30-2025	31-Dec-2024
Shareholders' equity	348	1 755
Provisions for contingencies and charges	10	12
Financial liabilities	417	643
Trade payables	942	913
Tax and social security liabilities	913	1025
Other liabilities	139	34
Deferred income	844	1 133
Cumulative translation adjustment
Total liabilities	3 613	5 515

Cash and cash equivalents at June 30, 2025 stood at €1,721,000.179 K€ lower than at the end of December 2024. This position takes into account the partial repayment of 600 K€ on the 1 M€ loan granted to
OncoDNA in August 2023, with the remaining €400,000 to be repaid in the second half of 2025.

At this cash level and based on the current rate of consumption, the Company estimates that its
free cash flow allows us to continue our business until between the end of 2025 and the end of 2025
and the first quarter of 2026, with no new external financing.

About IntegraGen
IntegraGen specializes in the genomics of cancer and genetic diseases. Backed by highly experienced, qualified teams, IntegraGen is a major player in DNA sequencing services and genomic data interpretation software. The company manages one of the largest NGS laboratories in France and operates for leading research institutes. IntegraGen harnesses the potential of high-throughput sequencing to offer patients the promise of precision medicine. IntegraGen has over 40 employees and generated revenues of 8.5 million euros in
2024.